Managing quality risks across APIs, excipients, botanicals and food supplements

Not all raw materials carry the same risks—but every raw material has the potential to impact patient safety. Global pharmaceutical and nutraceutical supply chains source thousands of materials from suppliers across dozens of countries, and every ingredient entering the process carries risk from contamination, variability, adulteration, inadequate controls, transportation conditions, or outright fraud.

The challenge is not to eliminate risk—an impossible task—but to identify, assess, control, and continuously monitor it using a science- and risk-based approach, as reinforced by ICH Q9 (Quality Risk Management), ICH Q10 (Pharmaceutical Quality System), ICH Q11, and global GMP regulations.^[6][7]

Why Risk-Based Raw Material Management Matters

Even with validated manufacturing processes and robust analytical methods, poor-quality raw materials can result in:

• Product recalls and regulatory observations
• Therapeutic failure or unexpected toxicity
• Manufacturing deviations and stability failures
• Supply chain disruptions and reputational damage

Both incidents trace back to raw materials—contaminated excipients and unqualified APIs—not to failures in finished-product testing. Health authorities increasingly expect companies to move beyond routine testing and adopt risk-based qualification and lifecycle management strategies.^[3]

Understanding Quality Risk Management (QRM)

ICH Q9(R1) defines Quality Risk Management as a systematic process for the assessment, control, communication, and review of risks to product quality throughout the product lifecycle.^[6] Applied to raw materials, QRM helps organizations answer:

• Which materials present the highest patient risk?
• Which suppliers require greater oversight?
• Where should analytical testing be intensified?
• Which changes require regulatory assessment?
• How frequently should suppliers be requalified?

Rather than treating every material equally, organizations allocate resources based on scientific understanding and potential patient impact.

Managing Risk Across Raw Material Categories

The principles of qualification are universal, but the nature of quality risk differs significantly by material.

APIs: The Highest Clinical Impact

Common risks include incorrect identity, potency variability, genotoxic impurities, nitrosamines, residual solvents, polymorphic changes, and microbial or endotoxin contamination. Even a small shift in crystal form or impurity profile can alter clinical performance and regulatory compliance.

• Mitigation: supplier qualification and audits, independent identity testing, impurity and nitrosamine risk assessment, stability evaluation, and ongoing supplier performance monitoring

Excipients: More Than "Inactive" Ingredients

Excipients are often mistakenly viewed as low-risk because they carry no therapeutic activity. But functional variability, moisture, particle size differences, and supplier process changes can cause tablet capping, dissolution failures, poor content uniformity, and manufacturing failures—as the DEG-in-glycerin cough syrup tragedies have repeatedly shown.^[1][2]

• Mitigation: functionality testing, compatibility studies, compendial compliance verification, and confirmed supplier manufacturing consistency

Botanical Ingredients: High Variability, High Risk

Botanical composition varies naturally with geographic origin, climate, soil, harvest timing, and processing method. Species substitution, deliberate adulteration, heavy metals, pesticide residues, and mycotoxins are recurring risks that can affect efficacy, safety, and label claims.

• Mitigation: botanical authentication, chromatographic fingerprinting, marker compound analysis, DNA-based identification where appropriate, and agricultural practice verification

Food Supplement Ingredients: Increasing Regulatory Expectations

Rapid growth in consumer demand has come with heightened regulatory scrutiny. Adulteration, heavy metals, microbial contamination, mislabeled potency, and economically motivated fraud can lead to consumer harm and regulatory enforcement.

• Mitigation: supplier qualification, ingredient authentication, identity and contaminant testing, and ongoing surveillance of supplier performance

Building a Risk-Based Qualification Framework

Rather than applying identical controls to every material, organizations should score risk across several factors:

Lifecycle Risk Management

Risk management doesn't end after supplier approval. Organizations should continuously monitor:

• Supplier performance trends and deviations
• Out-of-specification results and complaints
• Regulatory inspection findings and recalls
• Change notifications and audit outcomes

Periodic requalification ensures supplier performance remains consistent over time, not just at the point of initial approval.

Digital Transformation in Quality Risk Management

Leading organizations are shifting from reactive quality systems to predictive quality management, adopting:

• AI-assisted supplier risk scoring
• Digital supplier qualification platforms
• Predictive analytics for quality trends
• Electronic Quality Management Systems (eQMS)
• Real-time supplier performance dashboards

These technologies enable organizations to identify potential issues before they affect manufacturing or patients.^[7]

Common Mistakes Organizations Should Avoid

• Relying solely on supplier Certificates of Analysis
• Treating all materials as equal risk
• Infrequent supplier requalification
• Limited understanding of supplier manufacturing processes
• Weak communication between Procurement, Quality, Manufacturing, and Regulatory Affairs

A mature quality culture treats supplier management as a strategic responsibility, not an administrative task.

Our Insights

Managing quality risk across APIs, excipients, botanicals, and food supplements is no longer simply a GMP expectation—it is a strategic imperative. Each category presents distinct challenges that require tailored qualification strategies, scientific understanding, and continuous oversight. As supply chains globalize and regulatory expectations tighten, the organizations that treat risk-based quality management as a core capability—not a compliance checkbox—are the ones that anticipate problems instead of reacting to them.^[6][7]

Building a Risk-Based Quality Program Across Your Supply Chain?

Himaveda helps pharmaceutical, biotechnology, nutraceutical, and herbal product companies implement science-driven, risk-based raw material qualification and supplier management programs aligned with global regulatory expectations:

• Quality Risk Management (ICH Q9) implementation
• Supplier qualification and audit readiness
• Risk-based material classification
• API, excipient, botanical, and food supplement qualification strategies
• CMC documentation and regulatory submissions
• Change control and lifecycle management
• GMP inspection preparedness and remediation
• Regulatory consulting across US FDA, EMA, MHRA, WHO, and other global markets

Because effective quality risk management doesn't start in the manufacturing facility—it starts with understanding the risks associated with every ingredient that enters it.

Key Takeaways

• Not every raw material carries the same risk—resources should follow scientific understanding of patient impact, not treat every material identically.^[6]
• Recent DEG-contaminated excipient and nitrosamine-contaminated API incidents show that quality failures usually originate upstream of manufacturing, not at finished-product release.^[1][2][4]
• A risk-based framework—scored across material criticality, supplier risk, supply chain complexity, and patient risk—directs the strongest controls where they matter most.^[7]